Holen Sie sich die Stockscreener-App
24.73
1.19%
0.35
Schlusskurs vom Vortag:
$24.38
Offen:
$24.68
24-Stunden-Volumen:
4.08M
Relative Volume:
0.41
Marktkapitalisierung:
$10.45B
Einnahmen:
$5.06B
Nettoeinkommen (Verlust:
$-2.22B
KGV:
-4.2491
EPS:
-5.82
Netto-Cashflow:
$-3.96B
1W Leistung:
-10.65%
1M Leistung:
-7.50%
6M Leistung:
-47.32%
1J Leistung:
-79.89%
1-Tages-Spanne:
$24.53
$25.32
1-Wochen-Bereich:
$23.70
$28.52
52-Wochen-Spanne:
$23.15
$170.47
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.72 | 10.45B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.52 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
539.20 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
551.97 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.12 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.21 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna study shows immune response in older adults for a combo flu and COVID-19 shot - New Castle News
Collar Capital Management LLC Invests $898,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Banque Transatlantique SA Purchases New Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Axa S.A. Sells 38,456 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
PDT Partners LLC Has $280,000 Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna claims to have combined flu and COVID-19 vaccines - CBS News
Kovitz Investment Group Partners LLC Sells 40,925 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna study shows immune response in older adults for a new combo flu and COVID-19 shot - kotatv.com
Moderna Stock: Analyst Estimates & Ratings - Nasdaq
How effective will Moderna's combo Covid and flu mRNA shot be? - KSNV
Moderna, Inc. (NASDAQ:MRNA) Stake Lifted by Northern Trust Corp - MarketBeat
Moderna (MRNA) and Pfizer/BioNTech Vaccines Under FDA Review - GuruFocus
FDA advisory panel to discuss makeup of updated COVID shots - Seeking Alpha
MRNA Sees Surge in Options Activity with Notable Imbalance | MRNA Stock News - GuruFocus
June 27th Options Now Available For Moderna (MRNA) - Nasdaq
Moderna's Combo Flu and COVID Shot Shows Promise - El Paso Inc.
197,500 Shares in Moderna, Inc. (NASDAQ:MRNA) Bought by Cutter Capital Management LP - MarketBeat
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 | MRNA Stock News - GuruFocus
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 - The Derrick
RFK Jr. Takes Aim at Covid Shots for Kids, Worrying Vaccine Experts - Bloomberg
Combo flu and COVID-19 shot shows promise in new Moderna study - LiveNOW from FOX
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 - marketscreener.com
Moderna Vaccine Study - Tulsa World
Cantor Fitzgerald L. P. Purchases New Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Dimensional Fund Advisors LP Has $69.34 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
BLI Banque de Luxembourg Investments Takes Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
GraniteShares adjusts Moderna ETP in upcoming consolidation By Investing.com - Investing.com UK
This Week's Healthcare Earnings: Moderna, CVS, Hims & Hers - Law360
Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator - Barron's
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1 - The Globe and Mail
Redburn Atlantic Adjusts Moderna Price Target to $53 From $52, Maintains Neutral Rating - marketscreener.com
Public Employees Retirement Association of Colorado Trims Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
mRNA Vaccines: Evolving Pipelines Across Infectious Disease, Oncology & Rare Disorders - openPR.com
Moderna, Inc. (NASDAQ:MRNA) Stock Position Increased by Lido Advisors LLC - MarketBeat
Price T Rowe Associates Inc. MD Has $44.62 Million Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Envestnet Asset Management Inc. Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
On the Move: Moderna's Cronin Moves to Medtronic Diabetes - O'Dwyer's PR
Ex-Moderna brand chief Kate Cronin joins Medtronic Diabetes as marketing lead - Medical Marketing and Media
Moderna Sharpens Pipeline Focus As COVID-19 Vaccine Demand Ebbs In Q1 - Barchart.com
The Manufacturers Life Insurance Company Acquires 267,990 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock Crumbles As Vaccine Troubles Rattle Its Topline - MSN
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Pinebridge Investments L.P. - MarketBeat
Moderna Q1 Earnings Ahead: Analysts expect loss amid increased regulatory scrutiny - MSN
Moderna, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MRNA - ACCESS Newswire
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Aquatic Capital Management LLC - MarketBeat
UBS Analyst Lowers Price Target for MRNA, Maintains Buy Rating | - GuruFocus
XTX Topco Ltd Decreases Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Barclays Lowers Price Target on Moderna (MRNA) to $40.00 | MRNA Stock News - GuruFocus
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moderna Inc-Aktie (MRNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SAGAN PAUL | Director |
Mar 03 '25 |
Buy |
31.76 |
31,620 |
1,004,251 |
312,027 |
| Klinger Shannon Thyme | Chief Legal Officer |
Dec 09 '24 |
Sale |
44.68 |
529 |
23,637 |
20,446 |
2.11%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):